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T he gastrointestinal (GI) tract is the most com-monly involved site of extranodal non-Hodgkin’s 
lymphomas.  The predominant subtypes of lymphomas 
are different according to the site of the GI tract: mu-
cosa-associated lymphoid tissue (MALT) lymphoma for 
the stomach (46.2%) [1],  follicular lymphoma for the 
duodenum (38%) [2],  and diffuse large B-cell lym-
phoma (DLBCL) for the small and large intestines 
(41%) [3].  DLBCL of the small intestine is a rare dis-
ease but sometimes causes abdominal pain,  intestinal 
obstruction or perforation.  Our studies focusing on 
clinicopathological features of primary intestinal 
DLBCL revealed that perforation was one of the inde-
pendent poor prognostic factors in addition to the pre-
dominance of activated B-cell (ABC) phenotype [4 , 5].
A20,  also known as tumor necrosis factor alpha-in-
duced protein 3 (TNFAIP3),  is located on chromosome 
band 6q23 and negatively regulates the NF-κB pathway,  
which is dysregulated by several types of genetic alter-
ations including oncogenic mutations of MALT1 and 
CARD11 [6].  Deletion of A20 (TNFAIP3) was reported 
Acta Med.  Okayama,  2018
Vol.  72,  No.  1,  pp.  23-30
CopyrightⒸ 2018 by Okayama University Medical School.
http ://escholarship.lib.okayama-u.ac.jp/amo/Original Article
A20 (TNFAIP3) Alterations in Primary Intestinal Diffuse  
Large B-cell Lymphoma
Masayoshi Fujiia,b,  Katsuyoshi Takataa＊,  Shih-Sung Chuangc＊,  Tomoko Miyata-Takataa,   
Midori Andod,  Yasuharu Satoa,  and Tadashi Yoshinoa
aDepartment of Pathology,  Okayama University Graduate School of Medicine,  Dentistry and Pharmaceutical Sciences,   
Okayama 700-8558,  Japan,  bDepartment of Pathology,  St. Mary’s Hospital,  Himeji,  Hyogo 670-0801,  Japan,   
cDepartment of Pathology,  Chi-Mei Foundation Hospital,  Tainan 710,  Taiwan,   
dDepartment of Pathology,  Kagawa Prefectural Central Hospital,  Takamatsu 760-8557,  Japan
The gastrointestinal (GI) tract is the most frequently involved site of extranodal non-Hodgkin lymphomas,  and 
diffuse large B-cell lymphoma (DLBCL) is the most common subtype occurring in the GI tract.  TNFAIP3 (A20) 
genetic alterations were reported to be involved in DLBCL’s pathogenesis and a portion of GI-DLBCL cases har-
bor this alteration.  However,  the frequency and clinicopathological relations focusing on small and large intes-
tinal DLBCL are unclear.  Here,  we examined A20 deletion and protein expression and analyzed the clinicopath-
ological features of 52 cases of primary intestinal DLBCL.  The most frequently involved site was the ileocecal 
region (75%),  followed by small bowel (13.5%) and large intestine.  Immunohistochemically,  the ileocecal cases 
expressed BCL6 (p = 0.027) and MUM1 (p = 0.0001) significantly more frequently than the small intestinal cases.  
Six of 47 cases (13%) had A20 heterozygous deletion,  whereas all 6 heterozygously deleted cases had detectable 
A20 protein expression.  In summary,  A20 abnormality was less prevalent among intestinal DLBCLs with some 
discordancy between gene deletion and protein expression.  Although the A20 alteration status did not affect any 
clinicopathological characteristics in this series,  further studies exploring alterations of A20 and other NF-κB 
components in primary intestinal DLBCL are needed.
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in several types of lymphoma such as DLBCL of the 
ABC phenotype,  MALT lymphoma,  Hodgkin lym-
phoma,  and Epstein-Barr virus (EBV)-associated lym-
phoma.  A20 is a dual-function enzyme that adds and 
subtracts ubiquitin moieties to deactivate and degrade 
receptor-interacting protein (RIP),  an essential media-
tor of the proximal TNFR1 signaling complex [7].  A20 
restricts toll-like receptor-induced NF-κB signals by 
deubiquitylation and also regulates MAP kinase signal-
ing cascades.  Further,  A20 restrains inflammatory 
responses and acts as an anti-apoptotic factor,  regulat-
ing influences on immune homeostasis [8].
Although approx.  20% of DLBCL cases were 
reported to carry abnormalities in the A20 gene [9],  the 
frequency of A20 alterations and its clinicopathological 
significance in intestinal DLBCL are not characterized.  
In the present study,  we investigated A20 deletion and 
protein expression and analyzed their significance in 56 
cases of primary intestinal DLBCL.
Materials and Methods
Patient selection. Fifty-eight surgically resected 
intestinal DLBCL samples (obtained from 1990 to 2012,  
Chi-Mei Foundation Hospital,  Taiwan and affiliated 
hospitals) were used in this study,  and they are the same 
cases series used in the report by Lu et al.  [5].  We 
applied strict inclusion criteria for primary intestinal 
lymphoma according to the American Joint Committee 
on Cancer Staging Manual,  which is a modification of 
the Ann Arbor system.  We excluded cases of secondary 
involvement from other organs in this study.  The intes-
tinal site was classified according to the criteria of Koch 
et al.: duodenum,  small intestine,  ileocecum,  colon,  
and rectum [10].  The histologic diagnosis of each case 
was made according to the criteria by the current World 
Health Organization classification [11].
A total of 56 formalin-fixed paraffin embedded tis-
sue (FFPET) samples were used for tissue microarray,  
and two whole resected FFPETs were used for immuno-
histochemical (IHC) and genotypic studies.  Our study 
was approved by the Ethics Committee and Institu-
tional Review Board of Okayama University Hospital 
(ID no. 493) and Chi-Mei Medical Centre (ID no. 
10102-016).
FISH analysis for A20. A20 deletion was investi-
gated by dual-color fluorescence in situ hybridization 
(FISH) on FFPETs using s spectrum orange-labeled A20 
probe (BAC clone RP11-783B20) and spectrum green- 
labeled centromeric probe for chromosome 6 (CEP6) 
(Vysis/Abbott Molecular Laboratories,  Des Plaines,  IL,  
USA) according to the manufacturers’ instructions [12].  
The cells were scored only when 2 internal positive con-
trol signals (CEP6) were present,  and the signal ratio of 
A20 and CEP6 was calculated to evaluate the A20 status.  
In DLBCL,  the threshold for determining A20 homozy-
gous deletions was the fraction of signals ranging from 
20% to 60%,  and that for heterozygous deletions was 
from 60% to 80% as described [13].
IHC analysis. IHC staining was performed using 
an automated Bond Max autostainer (Leica Biosystems,  
Melbourne,  Australia) and a Ventana XT autostainer 
(Ventana Medical Systems,  Tucson,  AZ,  USA).  The 
clones and dilutions of the primary antibodies used for 
this study were as follows: A20 (EPR2663,  [1 : 100],  
Epitomics,  Burlingame,  CA,  USA),  CD20 (L26,  
[1 : 200],  Novocastra Laboratories,  Newcastle Upon 
Tyne,  UK),  CD10 (56C6,  [1 : 50],  Novocastra),  BCL6 
(D8,  [1 : 250],  Santa Cruz,  CA,  USA),  MUM1 
(MUM1p,  [1 : 50],  Dako,  Glostrup,  Denmark),  BCL2 
(Bcl-2,  [1 : 40],  Dako),  c-MYC (9E10,  [1 : 50],  Santa 
Cruz).
In accord with previous reports,  tumors that were 
comprised of at least 20% of A20-positive cells were 
scored as positive [14].  When the internal positive con-
trol cells were not clearly positive for A20,  the sample 
was classified as “indeterminate” or “equivocal.” In the 
“undetermined” groups,  the tumor cells were negative,  
and in the “equivocal” groups,  the tumor cells were 
weakly positive.
Statistical analysis. Overall survival (OS) was 
measured from the date of diagnosis to death from any 
cause.  Event-free survival (EFS) was not available 
because of paucity of data of most cases.  Survival 
curves were generated by the Kaplan-Meier method,  
and the value was compared by log-rank test.  Fisher’s 
exact test or chi-squared test was used.  We considered 
p-values < 0.05 significant.
Results
Patient characteristics. Clinical data was avail-
able for 52 of the 58 patients,  including 29 men (56%) 
and 23 women (44%).  The median age was 64 years 
(range,  23-87 years).  The tumor sizes ranged from 2.4 
to 16 cm with a mean size of 8.4 cm.  The most fre-
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quently involved site was the ileocecal region (39 of 52 
patients,  75%),  followed by the small bowel (jejunum 
and ileum,  7 of 52 patients,  13.5%) (Table 1).  Two 
patients had multiple sites of tumors: one involving the 
small intestine and colon,  and the other involving the 
duodenum,  small intestine and ileocecal region.  The 
median follow-up time was 21 months (range,  0.2-210 
months).
Pathological features. According to the DLBCL 
tumor morphology,  IHC findings were evaluable for 52 
samples,  and the cell-of-origin was determined using 
Hans’ algorithm.  Sixteen cases (31%) were GCB-type,  
and 36 (69%) were non-GCB-type (Figs. 1 and 2).  
Ileocecal samples were significantly more frequently 
positive for BCL6 (p = 0.027) and MUM1 (p = 0.0001) 
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Table 1　 Clinicopathological features of 52 Primary Intestinal DLBCL cases
LDH,  lactate dehydrogenase; PS,  performance status; IPI,  International Prognostic Index.
Factors No. of cases
Age
＜59 18
≧60 34
Sex
man 29
woman 23
Sites of origin
duodenum 2
small intestine 7
ileocecum 39
Colon 1
rectum 1
multiple intestinal sites 2
Tumor morphology
centroblastic 49
Immunoblastic 3
other 0
Tumor size
＜8 cm 27
≧8 cm 19
Depth
＜subserosa 21
≧serosa 24
Perforation
no 42
yes 10
Ulcer
no 37
yes 5
Serum LDH elevation
no 23
elevated 11
Factors No. of cases
Immunohistochemical status
A20 － 4
＋ 48
CD10 － 40
＋ 12
BCL2 － 14
＋ 38
BCL6 － 9
＋ 43
MUM1 － 12
＋ 39
c-MYC － 37
＋ 13
Subtypes by Hans classiﬁcation
GCB 16
non-GCB 36
A20 status by FISH
no deletion 41
heterozygous deletion 6
Lugano stage
I 22
II 30
PS
0～1 24
2～4 4
IPI
0～1 13
2～5 12
Adjuvant chemotherapy
no 18
yes 34
＋
＋ ＋
－
－
－
GCB type non-GCB type
CD10 MUM1
GCB type
BCL6
MUM1 +/‒ non-GCB type
12 cases 27 cases
4 cases
40 cases
9 cases
31 cases52 cases
Fig. 1　 Immunohistochemical subtypes according to Hans crite-
ria.
compared to the small intestinal cases.  Thirty-eight of 
the 52 (73%) samples were positive for BCL2,  and 13 of 
15 (26%) were positive for MYC. Six (12%) cases were 
BCL2 and MYC double-expressing DLBCL cases.
A20 deletion. Forty-seven of the 52 samples 
showed evaluable FISH signals.  Six of 47 cases (13%) 
had A20 heterozygous deletion (Fig. 3),  whereas there 
was no case with homozygous deletion.  The clinico-
pathological features of these six A20-deleted cases are 
summarized in Table 2.  The median age of the 6 
patients (4 men,  2 women) was 63 (range 51-81 years).  
The most frequently involved site was the ileocecal 
region (four cases,  67%) with a mean tumor size of 
8.2 cm.  Perforation was detected in 2 cases (33%),  
which led to death in both cases within 7 months.  In a 
median follow-up time of 9 months,  4 patients (67%) 
were dead.  In a univariate analysis,  there were no sig-
nificant differences between A20-heterozygously deleted 
and non-deleted cases including OS (p = 0.63).  The 
clinicopathological features of these 6 heterozygous A20 
deletion cases and the 41 deletion-negative cases are 
summarized in Table 3.
IHC findings and their correlation with clinico-
pathological characters and prognosis. Forty-six of 
52 samples were evaluable for the A20 IHC analysis.  
Forty-two samples (91%) were positive,  and the remain-
ing 4 samples (9%) were negative.  All 6 cases with a 
heterozygous A20 deletion were positive for A20 IHC.
Of the six A20-heterozygously-deletion cases,  5 were 
non-GCB-type and one was GCB-type.  The median age 
of the 4 patients (2 men,  2 women) with negative A20 
IHC was 63 (range 61-83 years).  The ileocecal region (3 
cases,  75%) was the most involved site,  with a mean 
tumor size of 7.0 cm.  Of these 4 patients,  there was no 
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Fig. 2　 Tissue array samples (2 cases) of hematoxylin-eosin stain (A) and immunostains (B,  A20; C,  CD10; D,  BCL6; E,  MUM1),  
(Olympus BX51).
5µm
Fig. 3　 FISH analysis of DLBCL case performed with a combina-
tion of A20 probe (orange) and chromosome 6 centromeric probe 
(green).  Two green signals (yellow arrowheads) and one red signal 
(white arrows) are seen in one cell,  indicating heterozygous dele-
tion of the A20 gene (Olympus IX71).
intestinal perforation or mortality in a median fol-
low-up time of 57 months.  Of these A20 IHC-negative 
patients,  2 were non-GCB-type and 2 were GCB-type.
The adjuvant chemotherapies were performed with 
the regimens of R-CHOP (rituximab,  cyclophospha-
mide,  doxorubicin,  vincristine and prednisone) (12 
cases,  39%),  CHOP (4 cases,  13%),  CEOP (etoposide 
substituted for doxorubicin) (8 cases,  26%),  and COP 
(4 cases,  13%).  Other regimens included R-hyper 
CVAD (rituximab with hyperfractionated cyclophos-
phamide,  vincristine,  doxorubicin and dexametha-
sone,  1 case,  3%),  rituximab,  etoposide and cyclophos-
phamide (1 case,  3%),  rituximab and cyclophosphamide 
(1 case,  3%).  The clinicopathological factors were not 
significantly different among the six A20-deleted,  four 
A20 IHC-negative,  and the remaining 41 patients,  
probably because the sample sizes of the former 2 
groups were too small.
Discussion
We examined A20 deletion and protein expression 
using primary intestinal DLBCL cases.  CARD11 and 
MYD88 mutations are involved in the NF-κB pathway 
alterations including A20,  and these are frequent events 
in non-GCB type DLBCL.  We found that 6 of 52 cases 
(13%) showed A20 heterozygous deletion,  but all these 
cases were positive for A20 protein expression.  On the 
other hand,  4 of the 52 cases were negative for A20 pro-
tein expression,  whereas no A20 deletion was observed.  
We demonstrated that A20 deletion did not necessarily 
cause A20 protein down-expression [13]; some cases 
with heterozygous deletion showed A20 IHC positivity 
although cases with homozygous deletion showed A20 
IHC negativity.  It has also been reported that not only 
A20 deletion but also A20 promoter hypermethylation 
could contribute to A20 down-expression [15].  Therefore,  
in the 4 present A20 non-deleted and IHC-negative 
cases,  the IHC negativity might have been caused by 
promoter hypermethylation.
We hypothesized that only A20 haplo-insufficiency 
from heterozygous deletion might cause lymphoma-
genesis in B-cell lymphoma.  Honma et al.  reported that 
monoallelic A20 inactivation as well as biallelic A20 
inactivation was frequently found in ABC-phenotype 
DLBCLs and mantle cell lymphomas,  and they demon-
strated that A20 induced resistance to apoptosis and 
increased colony formation ability in human EB-LCL 
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(Epstein Barr virus lymphoblastoid cell line) even with 
a partial knockdown [15].  These results might support 
the role of A20 gene in our cohort.
We also speculated that not only A20 heterozygous 
deletion but also other gain-of-function mutations such 
as CARD11 and MYD88 which are frequently found in 
ABC-type DLBCLs could affect the lymphomagenesis.  
Although the cell types were different,  Wolfrum et al.  
reported that pro-atherosclerotic NF-κB target gene was 
elevated and atherosclerosis was increased in A20 hap-
lo-insufficient mice,  so that A20 resulted in NF-κB 
deregulation [16].  This result might support the rela-
tionship between A20 and NF-κB.
Because we had only paraffin-embedded samples for 
tissue microarray,  our study was strictly limited to 
immunohistochemical and FISH analyses.  We could 
not obtain further data including those from a real-time 
reverse transcription-polymerase chain reaction 
(RT-PCR),  mutational analysis,  or methylation-spe-
cific PCR analysis.  In order to clarify the specific mech-
anisms in the NF-κB pathway,  some DLBCL-derived 
cell lines (probably established from pleura or lymph 
node) must be used.  The gastrointestinal tract is one of 
the specific extranodal sites with special immune sys-
tems,  and it is strongly affected by antigen stimulation 
and other cytokines compared to other organs.  When 
the above-mentioned types of cell lines are used,  con-
clusions that differ from those observed with intestinal 
DLBCL (as in the present study) might be obtained.  To 
the best of our knowledge,  there are no DLBCL cell 
lines derived from intestine,  and we suspect that it 
might be difficult to demonstrate the functional status of 
A20 in primary intestinal DLBCLs.
There were some discrepancies between our present 
FISH and IHC results,  and we speculate that a FISH 
analysis could be a better way for determining the A20 
genetic status compared to immunohistochemical anal-
yses.  Giulino et al.  reported the first immunohisto-
chemical findings for A20 [14].  They observed that an 
A20-biallelic mutation case (1 case) was negative for 
A20 IHC,  whereas cases with A20 mutation and/or 
monoallelic deletion frequently retained reactivity 
toward A20 IHC.
Based on comprehensive gene expression analyses,  
DLBCLs are subclassified into GCB,  non-GCB,  and 
unclassified types,  and there are significant prognostic 
differences between the GCB type and the non-GCB 
type [17].  It is thus important to classify the cells-of-or-
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Table 3　 Clinicopathological features of A20 heterozygous 
deleted cases vs. deletion negative cases＊
A20 status by FISH
heterozygous deletion no deletion P-value＊＊
Total 6 41
Age
＜59 2 13 1
≧60 4 28
Sex
man 4 25 1
woman 2 16
Tumor site
Duodenum 0 2
0.322
Small intestine 3 11
Ileocecum 2 24
Colon 0 2
Rectum 0 1
Mutiple sites 1 1
Tumor size
＜8 cm 4 20 0.685
≧8 cm 2 16
Perforation
none 4 35 0.267
yes 2 6
Immunohistochemical status
A20 － 0 4 1
＋ 6 37
CD10 － 6 31 0.317
＋ 0 10
BCL2 － 1 12 1
＋ 5 29
BCL6 － 1 7 1
＋ 5 34
MUM1 － 1 9 1
＋ 5 31
c-MYC － 5 32 1
＋ 1 7
Subtypes by Hans classiﬁcation
non-GCB type 5 28 0.653
GCB type 1 13
serum LDH elevation
no 3 18 1
yes 1 8
adjuvant chemotherapy
None 2 14
1
R-CHOP 3 9
CHOP 1 3
CEOP 0 8
COP 0 4
Others 0 3
Survival status
alive 2 23 0.398
dead 4 18
Followed months
＜20 months 4 16 0.379
≧20 months 2 25
LDH,  lactate dehydrogenase; CHOP,  cyclophosphamide,  doxorubicin,  vincristine and 
predonisone; R-CHOP,  Rituximab and CHOP; CEOP,  cyclophosphamide,  etoposide,  
vincristine and predonisone; COP,  cyclophosphamide,  vincristine and predonisone.
＊Insuﬃcient 5 cases by FISH analysis were excluded.
＊＊Fisherʼs Exact test.
igin by immunohistochemistry in routine practice.  In 
primary gastrointestinal DLBCLs,  the frequency of the 
non-GCB type was reported to be 6-14% in the small 
intestine,  and 57% in the colon [18 , 19].  In the present 
series,  approx.  70% of the cases were non-GCB type.  
This relatively higher prevalence of the non-GCB type 
might be due to the higher proportion of ileocecal sam-
ples in this study and/or to genetic factors,  as DLBCL 
cases in Taiwan,  regardless of tumor sites,  have shown 
a relative high frequency (72.5%) of the non-GCB phe-
notype [20].
We have reported that perforation,  high 
Performance Status ( > 2),  and no adjuvant chemother-
apy were independent poor-prognosis factors for pri-
mary intestinal DLBCL [4 , 5].  In addition,  tumor size 
> 8 cm was a new independent poor-prognosis factor 
(p = 0.03,  95% CI: 1.11-8.34) (Table 1).  To the best of 
our knowledge,  no study has demonstrated that the 
tumor size of intestinal DLBCL could be an indepen-
dent predictor of prognosis.  The Lugano classification 
does not refer to the tumor size in intestinal lympho-
mas [21].  Large-sized tumors might carry a higher risk 
of perforation,  and thus large tumor size could be a 
poor-prognosis factor.
In conclusion,  we observed that A20 abnormality 
was less prevalent among intestinal DLBCLs than 
DLBCLs at other anatomic sites.  We also observed 
some discordancy between gene deletion and protein 
expression.  Although the A20 alteration status did not 
affect any clinicopathological characters in this series,  
further studies exploring alterations of A20 and other 
NF-κB components in primary intestinal DLBCL are 
needed.
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